Daratumumab-Based Therapy Effective Treating Multiple Myeloma

Janssen recently announced positive results from the phase 3 ALCYONE clinical trial, which demonstrated that daratumumab (Darzalex) plus bortezomib, melphalan, and prednisone (VMP) improved the clinical outcomes of patients with multiple myeloma (MM), according to a press release.
 
In patients with MM who were ineligible for autologous stem cell transplant, the daratumumab combination reduced the risk of disease progression or mortality by 50%, according to Janssen.
 
“These phase 3 results for Darzalex demonstrated clinically meaningful improvements with a manageable safety profile,” said lead investigator Maria-Victoria Mateos, PhD. “Selecting the right treatment regimen is critical for patients who are newly diagnosed, especially if they are transplant ineligible, as these patients tend to be older and more frail. These findings strongly support this Darzalex frontline regimen as a new standard of care for these patients.”
 
After a median follow-up of 16.5 months, daratumumab plus VMP slashed the risk of progression in half compared with VMP therapy, according to the release.
 
Daratumuab was also observed to increase overall response rates compared with VMP alone, with 91% of patients treated with combination therapy and 74% of patients treated with VMP achieving an overall response, according to the study.
 
The addition of daratumumab more than doubled the rate of stringent complete response from 7% with VMP to 18%. Janssen also found that daratumumab nearly doubled the complete response rate.
 
Minimal residual disease negativity rate was observed to triple among patients treated with the combination therapy compared with VMP alone, according to the study.
 
However, progression-free survival for the combination therapy has yet to be determined.
 
Common treatment-emergent events included neutropenia, thrombocytopenia, anemia, and pneumonia. The most common adverse events included pneumonia, anemia, bronchitis, lower respiratory tract infection, upper respiratory tract infection, febrile neutropenia, and cardiac failure.
 
In November 2017, Janssen submitted a supplemental Biologics Application for daratumumab plus VMP for patients with MM. If approved, this would be the fifth approval for daratumumab and the first approval as a first-line therapy, according to the release.
 
“Darzalex offers compelling and consistent clinical benefit across all lines of therapy in multiple myeloma,” said Sen Zhuang, MD, PhD, vice president, Oncology Clinical Research, Janssen Research and Development. “These latest results convey the promise of Darzalex in newly diagnosed patients for whom the initial therapy is most critical for long-term survival.”


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Health care providers managing patients with MS should remain cognizant of the link between unhealthy lifestyle behaviors and depression risks.
The FDA advises health care providers to counsel patients receiving alemtuzumab on symptoms related to stroke and arterial dissection.
Stopping treatment with fingolimod (Gilenya) can cause the disease to become much worse than before the medicine was started or while it was being taken, FDA officials warned.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$